Results 151 to 160 of about 3,377,134 (229)

Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta‐Analysis of Randomized Clinical Trials

open access: yesEndocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
This network meta‐analysis of 4 randomized controlled trials (14,348 adults with type 2 diabetes, with or without established atherosclerotic cardiovascular disease) compared all clinically relevant doses of tirzepatide (1, 5, 10, 15 mg) against dulaglutide (0.75, 1.5, 4.5 mg).
Ahmed W. Hageen   +13 more
wiley   +1 more source

Tirzepatide and Weight Management

open access: yesJK Science
Tirzepatide is a once-weekly dual agonist, that acts on glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.
Vishal R. Tandon, Annil Mahajan
doaj  

Dipeptidyl Peptidase‐4 Inhibitors Associated Heart Failure Events in Adult Patients With Type‐2 Diabetes Mellitus Treated With Dipeptidyl Peptidase‐4 Inhibitors: A Systematic Review and Meta‐Analysis

open access: yesEndocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
DPP‐4 Inhibitors associated withheart failure events in patients with type‐2 diabetes. This study found statistically insignificant summary effect for all DPP‐4 inhibitors combined but found asignificant association of saxagliptin with heart failure events (RR = 1.24, 95% CI 1.05–1.47). Results are to be interpreted with caution.
Shishir Nepal, Shiva Prasad Nepal
wiley   +1 more source

The Evolution of Medications for Obesity Management

open access: yesJGH Open, Volume 10, Issue 9, September 2026.
ABSTRACT This narrative review provides an overview of progress in the development of obesity medications, including a synthesis of data describing the efficacy and safety of currently available agents and emerging therapeutic options. Historically, many obesity medications have been withdrawn from the market due to safety concerns.
Jaskirath Gill, Priya Sumithran
wiley   +1 more source

Metabolic Syndrome: From Mechanisms to Therapeutic Interventions

open access: yesMedComm, Volume 7, Issue 9, September 2026.
A comprehensive overview of molecular mechanisms delves into the potential disease mechanisms of metabolic syndrome, including complex mechanisms such as insulin resistance, chronic low‐grade inflammation, oxidative stress, and epigenetic modifications, and how these mechanisms contribute to the development of metabolic syndrome. Here, the relationship
Mengyao Yan, Qian Xiang
wiley   +1 more source

Association of Glucose‐Dependent Insulinotropic Polypeptide Levels With Cardiovascular Mortality in Patients With Acute Myocardial Infarction

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Florian Kahles   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy